Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antiviral drug
Biotech
Enanta's RSV antiviral crushes viral load in challenge study
Enanta said the data cleared the bar set by its other candidate, opening up opportunities to test the molecules as single agents and in combination.
Nick Paul Taylor
Sep 26, 2024 7:43am
Protease inhibitor outperforms Paxlovid protecting lungs of mice
Mar 14, 2024 6:30am
Enanta halts work on joint hMPV-RSV drug to extend cash to 2027
Nov 21, 2023 8:30am
J&J links antiviral to protection from dengue in challenge trial
Oct 20, 2023 9:30am
Atea dumps dengue drug as forecast R&D timelines, costs spiral
Mar 1, 2023 6:50am
Pfizer's hunt for Paxlovid sibling leads to low-profile biotech
Dec 6, 2022 9:35am
